Randomized, Double-blind, Multicenter Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-Release (OxyIR) Versus BTDS 5 in Subjects With Moderate to Severe Osteoarthritis (OA) Pain

Trial Profile

Randomized, Double-blind, Multicenter Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-Release (OxyIR) Versus BTDS 5 in Subjects With Moderate to Severe Osteoarthritis (OA) Pain

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2012

At a glance

  • Drugs Buprenorphine; Oxycodone
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Purdue Pharma
  • Most Recent Events

    • 29 Sep 2010 Checked against NCT record.
    • 29 Sep 2010 Checked against NCT record.
    • 28 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top